Cargando…

Cost accounting in the EDP-supported chemical laboratory

Detalles Bibliográficos
Autor principal:	Gibitz, H. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 1983
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547535/ https://www.ncbi.nlm.nih.gov/pubmed/18927904 http://dx.doi.org/10.1155/S146392468300022X

Ejemplares similares

EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1988)

EDP auditing : conceptual foundations and practice /
por: Weber, Ron (Ronald)
Publicado: (1982)

Up the EDP pyramid : the complete job hunting manual for computer professionals /
por: French, Jack, 1932-
Publicado: (1981)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2021)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

EDP-M plus sintilimab in the treatment of adrenocortical carcinoma: a case report
por: Zhang, Zhipeng, et al.
Publicado: (2022)

Correction for: ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
por: Wang, Liang, et al.
Publicado: (2023)

DHA Oral Supplementation Modulates Serum Epoxydocosapentaenoic Acid (EDP) Levels in Breast Cancer Patients
por: Molfino, Alessio, et al.
Publicado: (2019)

SIRT Is Required for EDP-Mediated Protective Responses toward Hypoxia–Reoxygenation Injury in Cardiac Cells
por: Samokhvalov, Victor, et al.
Publicado: (2016)

Plan de contingencias para un centro de procesamiento electrónico de datos EDP
por: Maldonado Díaz, Pablo
Publicado: (1998)

Assessment of drug–drug interaction potential with EDP‐305, a farnesoid X receptor agonist, in healthy subjects
por: Ahmad, Alaa, et al.
Publicado: (2022)

EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
por: Marotta, Christine, et al.
Publicado: (2022)

Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience
por: Laganà, Marta, et al.
Publicado: (2020)

Challenges faced by edentulous patients (EDPs) during complete denture prostheses (CDP) service delivery in Fiji – a qualitative study
por: Nand, Meenal, et al.
Publicado: (2022)

The effect of for-profit laboratories on the accountability, integration, and cost of Canadian health care services
por: Sutherland, Ross
Publicado: (2012)

Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP‐305, a novel farnesoid X receptor agonist
por: Erstad, Derek J., et al.
Publicado: (2018)

Efficacy of Treatment With PARP Inhibitor and Immunotherapy for Aggressive Adrenocortical Carcinomawith Cushing’s Syndrome Refractory to Treatment With EDP Chemotherapy and Mitotane
por: Greb, Alexandra C, et al.
Publicado: (2021)

Solutions entropiques et renormalisées de quelques E.D.P. non linéaires dans $L^1\-L
por: Kaouther, A
Publicado: (2003)

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model
por: Rhodin, Michael H. J., et al.
Publicado: (2021)

Cost Accounting
por: Rajasekaran, V
Publicado: (2010)

Cost Accounting
por: Alex, K
Publicado: (2012)

Predicting hospital accounting costs
por: Newhouse, Joseph P., et al.
Publicado: (1989)

EDP-938, un nuevo antiviral con actividad inhibidora frente a la nucleoproteína del virus respiratorio sincitial
por: Reina, Jordi, et al.
Publicado: (2022)

667. Preclinical Pharmacokinetic and Pharmacodynamic Characterization of EDP-938, a Novel and Potent NonFusion Replication Inhibitor of Respiratory Syncytial Virus
por: Jiang, Li-Juan, et al.
Publicado: (2019)

Cost accounting : traditions and innovations /
por: Barfield, Jesse T.
Publicado: (2003)

Cost accounting : analysis and control
por: Shillinglaw, Gordon
Publicado: (1972)

Cost accounting : traditions and innovations /
por: Barfield, Jesse T.
Publicado: (2001)

Differential Effects of 17,18-EEQ and 19,20-EDP Combined with Soluble Epoxide Hydrolase Inhibitor t-TUCB on Diet-Induced Obesity in Mice
por: Yang, Yang, et al.
Publicado: (2021)

EDP2PDF: a computer program for extracting a pair distribution function from an electron diffraction pattern for the structural analysis of materials
por: Liu, Hongwei, et al.
Publicado: (2023)

Management and cost accounting
por: Drury, Colin
Publicado: (1992)

Cost Accounting For Dummies
por: Boyd, Kenneth
Publicado: (2013)

Pricing and Cost Accounting
por: Oyer, Darrell
Publicado: (2011)

Cost accounting : a managerial emphasis /
por: Horngren, Charles T., 1926-
Publicado: (2000)

A novel non‐bile acid FXR agonist EDP‐305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
por: An, Ping, et al.
Publicado: (2020)

923. EDP-938, A Respiratory Syncytial Virus (RSV) antiviral, demonstrates a high barrier to resistance in a human challenge study
por: Levene, Rachel E, et al.
Publicado: (2023)

Synergistic activation of AMPK by AdipoR1/2 agonist and inhibitor of EDPs–EBP interaction recover NAFLD through enhancing mitochondrial function in mice
por: Song, Nazi, et al.
Publicado: (2023)

Financial Costs of Large Carnivore Translocations – Accounting for Conservation
por: Weise, Florian J., et al.
Publicado: (2014)

The Supportive Accountability Inventory: Psychometric properties of a measure of supportive accountability in coached digital interventions
por: Meyerhoff, Jonah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a3f8brnm3smseuhste4k7j19ah